65,437 trials
Cancer · Pain
Primary: Numeric Rating of Scale (From 0 to 10) of Pain and Possible Side Effects (Drowsiness, Confusion, Nausea) of Opioids — 2.22; 3.10; 2.83; 3.05 scores
ADHD
Primary: Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up…
Primary Insomnia
Primary: The Change From Baseline in Subjective Sleep Latency. — -19.1; -1.7 minutes — p=<0.05
Leukemia · Lymphoma
Primary: Number of Patients Without GVHD at 100 Days — 100 participants
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Heartburn
Primary: Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal — 0; 2; 1; 0 participants
Hypertension
Primary: Mean 24 Hour Ambulatory Systolic Blood Pressure (MASBP) in Systolic Hypertensive Patients Treated With Aliskiren (300 mg) for 4 Weeks on a High Sodium Diet Versus 4…
Vasomotor Rhinitis · Seasonal Allergic Rhinitis
Primary: Percentage of Participants That Preferred Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets for the…
Hypertension
Primary: Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.63; -9.19 mm Hg
Anemia
Primary: Maximum Observed Serum Concentration (Cmax) — 8545.33 ug/dL
Pancreatic Cancer
Primary: Overall Survival Time — 9.2; 11.0 Months — p=0.017
Type 2 Diabetes Mellitus
Primary: Saxagliptin Mean Maximum Observed Plasma Concentration (Cmax) — 8.57; 8.61; 11.36; 11.51 ng/mL
Head and Neck Cancer
Primary: 2-year Progression-free Survival Rate — 47 proportion of participants
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12 — -13.96; -11.64 mm Hg
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24 — -1.28; -1.18 Percent of Glycosylated Hemoglobin